Timothy Chiang

TiGenix Downgraded As Shares Soar Above BTIG's Price Target

Risks For Teva Remain As CEO Search Continues

Competition For Mylan's Generic Concerta Is Limited

Risks For Teva Remain As CEO Search Continues

Competition For Mylan's Generic Concerta Is Limited

Has Synergy Pharmaceuticals Become A Takeout Candidate Following 2 Recent Phase 3 Trial Successes?

Shire Could Have A Game Changer In The Making

Has Synergy Pharmaceuticals Become A Takeout Candidate Following 2 Recent Phase 3 Trial Successes?

Shire Could Have A Game Changer In The Making

Synergy Reports Positive Phase 3-Trial 1 Data

Key Exec Announcing His Retirement From Teva 'Creates More Uncertainties'